Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives

Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as neural apoptosis regulated convertase (NARC1), is a key modulator of cholesterol metabolism. PCSK9 increases the serum concentration of low-density lipoprotein cholesterol by escorting low-density lipoprotein receptors (LDLRs) from...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Acta Pharmacol Sin
Autors principals: He, Ni-ya, Li, Qing, Wu, Chun-yan, Ren, Zhong, Gao, Ya, Pan, Li-hong, Wang, Mei-mei, Wen, Hong-yan, Jiang, Zhi-sheng, Tang, Zhi-han, Liu, Lu-shan
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342665/
https://ncbi.nlm.nih.gov/pubmed/28112180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.134
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars